Table 5 : Statistical summary of differences in spectral intensity for SELDI-TOF MS spectra (Apo C-III1, Apo C-III1, Apo C-III2) between GDM cases and gestationally age matched controls.


Apo C-III0 concentration (µA)

  4-12 weeks* 16-22 weeks* 24-28 weeks* P value**
(16-22, 24-28 weeks)
U value (critical U)***
(16-22, 24-28 weeks)

Control 47 (16) 92 (22) 98 (16) 0.020, 0.009 13 (15), 9 (15)
Gestational Diabetes 53 (9) 40 (16) 40 (21) 0.149, 0.417 16 (11), 11(4)

Apo C-III1 concentration (µA)

  4-12 weeks* 16-22 weeks* 24-28 weeks* P value**
(16-22, 24-28 weeks)
U value (critical U)***
(16-22, 24-28 weeks)

Control 91 (45) 212 (71) 312 (104) 0.007, 0.001 8 (15), 3 (15)
Gestational Diabetes 146 (31) 200 (71) 359 (122) 0.215, 0.006 56 (41), 0 (4)

Apo C-III2 concentration (µA)

  4-12 weeks* 16-22 weeks* 24-28 weeks* P value**
(16-22, 24-28 weeks)
U value (critical U)***
(16-22, 24-28 weeks)

Control 21 (4) 40 (11) 51 (14) 0.003, 0.001 5 (15), 3 (15)
Gestational Diabetes 26 (4) 38 (16) 47 (29) 0.444, 0.018 67 (41), 2 (4)

Data are expressed as median spectral intensities (µA) (median [95% confidence interval) , n=4-5 GDM cases and n=8 gestationally age-matchedcontrols.
*median (95% confidence interval).
**, Mann-Whitney U test relative to 4-12 weeks.
***, critical value of U for statistical significance at p≤0.05.

Ippolito et al.Journal of Diabetes Research and Clinical Metabolism  2013 2:22DOI : 10.7243/2050-0866-2-22